Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis

British Journal of Dermatology

Volumn 175, Issue 1, 2016, Pages 157-162

  Kimball, A B ^a   Naegeli, A N ^b   Edson Heredia, E ^b   Lin, C Y ^b   Gaich, C ^b   Nikai E ^b   Wyrwich, K ^c   Yosipovitch, G ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c EVIDERA   (United States)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARICITINIB; ETANERCEPT; IXEKIZUMAB; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; CONVERGENT VALIDITY; DERMATOLOGY LIFE QUALITY INDEX; DISCRIMINANT VALIDITY; DISEASE SEVERITY; FEMALE; HUMAN; ITCH NUMERIC RATING SCALE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SELF REPORT; SHORT FORM 36; SYSTEMIC THERAPY; TEST RETEST RELIABILITY; TREATMENT RESPONSE; VALIDITY;

EID: 84982921555     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14464     Document Type: Article

References (27)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332:581–8.
2. Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26:314–20.
3. Yosipovitch G, Goon A, Wee J et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143:969–73.
4. Sampogna F, Gisondi P, Melchi CF et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151:594–9.
5. Reich A, Hrehorów E, Szepietowski JC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010; 90:257–63.
6. Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes 2009; 7:62.
7. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:401–7.
8. Verhoeven EW, Kraaimaat FW, van de Kerkhof PC et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007; 156:1346–9.
9. Amatya B, Wennersten G, Nordlind K. Patients' perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol 2008; 22:822–6.
10. Lewis-Beck C, Abouzaid S, Xie L et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence 2013; 7:199–205.
11. Janowski K, Steuden S, Bogaczewicz J. Clinical and psychological characteristics of patients with psoriasis reporting various frequencies of pruritus. Int J Dermatol 2014; 53:820–9.
12. Lebwohl M, Swensen AR, Nyirady J et al. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol 2014; 53:714–22.
13. Zhu B, Edson-Heredia E, Guo J et al. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol 2014; 171:1215–19.
14. European Medicines Agency (EMEA). Committee for medicinal products for human use (CHMP). Guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Psoriasis. London: EMEA, 2004.
15. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58:826–50.
16. Naegeli AN, Flood E, Tucker J et al. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis. Int J Dermatol 2015; 54:715–22.
17. Food and Drug Administration. Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools. Silver Spring, MD: U.S. Department of Health and Human Services, 2014.
18. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–16.
19. Basra MK, Fenech R, Gatt RM et al. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159:997–1035.
20. Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157:238–44.
21. Ware JE, Kosinski M, Keller SK. SF-36® Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, 1994.
22. Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn. New York, NY: McGraw-Hill, 1994.
23. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
24. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 2005; 16:73–81.
25. Roblin D, Wickramasinghe R, Yosipovitch G. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol 2014; 70:390–1.
26. Jenkins HH, Spencer ED, Weissgerber AJ et al. Correlating an 11-point verbal numeric rating scale to a 4-point verbal rating scale in the measurement of pruritus. J Perianesth Nurs 2009; 24:152–5.
27. Phan NQ, Blome C, Fritz F et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92:502–7.